Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
Recursion Pharmaceuticals reported mixed Q2 results with a net loss narrowing to $131 million and revenue falling to $7.67 million. Despite challenges, the company highlighted significant clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results